MedTrace Logo

Investigation of Vasodilation and Intensity of Headache Triggered by Glucagon Like Peptide-1 in Humans

NCT04232605 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2020-01-18

No results posted yet for this study

Summary

Studying glucagon-like peptide-1 (GLP-1) induced vasodilatory effects on extra - and intracerebral arteries and headache in healthy volunteers and migraine patients without aura.

Conditions

  • Headache, Migraine

Interventions

OTHER

GLP-1 peptide

Receive intravenous infusion of GLP-1. The dosage will be determined after a dose finding pilot study.

OTHER

Placebo

Receive intravenous infusion saline

Sponsors & Collaborators

  • Danish Headache Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-09
Primary Completion
2021-12-31
Completion
2022-01-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04232605 on ClinicalTrials.gov